AU2001239488B2 - Heterologous expression of neisserial proteins - Google Patents
Heterologous expression of neisserial proteins Download PDFInfo
- Publication number
- AU2001239488B2 AU2001239488B2 AU2001239488A AU2001239488A AU2001239488B2 AU 2001239488 B2 AU2001239488 B2 AU 2001239488B2 AU 2001239488 A AU2001239488 A AU 2001239488A AU 2001239488 A AU2001239488 A AU 2001239488A AU 2001239488 B2 AU2001239488 B2 AU 2001239488B2
- Authority
- AU
- Australia
- Prior art keywords
- protein
- fwd
- rev
- xhoi
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 335
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 316
- 241001212279 Neisseriales Species 0.000 title description 13
- 241000588650 Neisseria meningitidis Species 0.000 claims abstract description 17
- 230000004927 fusion Effects 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 48
- 150000001413 amino acids Chemical class 0.000 claims description 38
- 210000004899 c-terminal region Anatomy 0.000 claims description 19
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 238000013459 approach Methods 0.000 abstract description 29
- 238000000746 purification Methods 0.000 abstract description 18
- 230000001900 immune effect Effects 0.000 abstract description 6
- 241000588652 Neisseria gonorrhoeae Species 0.000 abstract description 5
- 230000030570 cellular localization Effects 0.000 abstract description 4
- 235000018102 proteins Nutrition 0.000 description 283
- 108010076504 Protein Sorting Signals Proteins 0.000 description 117
- 241000588724 Escherichia coli Species 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 48
- 239000000872 buffer Substances 0.000 description 40
- 239000012528 membrane Substances 0.000 description 37
- 235000001014 amino acid Nutrition 0.000 description 35
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 33
- 241000894006 Bacteria Species 0.000 description 31
- 102000039446 nucleic acids Human genes 0.000 description 31
- 108020004707 nucleic acids Proteins 0.000 description 31
- 150000007523 nucleic acids Chemical class 0.000 description 31
- 230000000844 anti-bacterial effect Effects 0.000 description 30
- 238000012217 deletion Methods 0.000 description 26
- 230000037430 deletion Effects 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000013598 vector Substances 0.000 description 25
- 239000006228 supernatant Substances 0.000 description 24
- 238000003556 assay Methods 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 239000013604 expression vector Substances 0.000 description 19
- 101000626900 Trieres chinensis Uncharacterized 5.5 kDa protein in ccsA-rps6 intergenic region Proteins 0.000 description 18
- 239000012634 fragment Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- 108020004705 Codon Proteins 0.000 description 17
- 102100031725 Cortactin-binding protein 2 Human genes 0.000 description 17
- 108020004414 DNA Proteins 0.000 description 17
- 238000002965 ELISA Methods 0.000 description 17
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 17
- 238000005119 centrifugation Methods 0.000 description 17
- 238000010367 cloning Methods 0.000 description 17
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 17
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 16
- 239000008188 pellet Substances 0.000 description 15
- 101710197985 Probable protein Rev Proteins 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 125000003729 nucleotide group Chemical group 0.000 description 13
- 230000002588 toxic effect Effects 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 12
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108091034117 Oligonucleotide Proteins 0.000 description 11
- 230000003197 catalytic effect Effects 0.000 description 11
- 238000011534 incubation Methods 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 239000008363 phosphate buffer Substances 0.000 description 10
- 108010094020 polyglycine Proteins 0.000 description 10
- 108090001030 Lipoproteins Proteins 0.000 description 9
- 102000004895 Lipoproteins Human genes 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 229920001817 Agar Polymers 0.000 description 8
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
- 108091006054 His-tagged proteins Proteins 0.000 description 8
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 108010079246 OMPA outer membrane proteins Proteins 0.000 description 8
- 108010013639 Peptidoglycan Proteins 0.000 description 8
- 239000008272 agar Substances 0.000 description 8
- 230000003321 amplification Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000004807 localization Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000003199 nucleic acid amplification method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 102100028146 F-box/WD repeat-containing protein 2 Human genes 0.000 description 7
- 101001060245 Homo sapiens F-box/WD repeat-containing protein 2 Proteins 0.000 description 7
- 108091006629 SLC13A2 Proteins 0.000 description 7
- 101710202138 Soluble lytic murein transglycosylase Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 241000040340 Oat mosaic virus Species 0.000 description 6
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000003456 ion exchange resin Substances 0.000 description 6
- 229920003303 ion-exchange polymer Polymers 0.000 description 6
- 210000001322 periplasm Anatomy 0.000 description 6
- 239000011347 resin Substances 0.000 description 6
- 229920005989 resin Polymers 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- 239000004257 Anoxomer Substances 0.000 description 5
- 238000009010 Bradford assay Methods 0.000 description 5
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 5
- 230000000922 anti-bactericidal effect Effects 0.000 description 5
- 239000007998 bicine buffer Substances 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 239000012737 fresh medium Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000002523 gelfiltration Methods 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 239000004220 glutamic acid Substances 0.000 description 5
- 230000010354 integration Effects 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 230000002101 lytic effect Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 4
- 101150026402 DBP gene Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 101000833492 Homo sapiens Jouberin Proteins 0.000 description 4
- 101000651236 Homo sapiens NCK-interacting protein with SH3 domain Proteins 0.000 description 4
- 101100100297 Human herpesvirus 8 type P (isolate GK18) TRM3 gene Proteins 0.000 description 4
- 102100024407 Jouberin Human genes 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 101150101223 ORF29 gene Proteins 0.000 description 4
- 101150075249 ORF40 gene Proteins 0.000 description 4
- 108700026244 Open Reading Frames Proteins 0.000 description 4
- 101100096140 Orgyia pseudotsugata multicapsid polyhedrosis virus SOD gene Proteins 0.000 description 4
- 239000007977 PBT buffer Substances 0.000 description 4
- 101100156835 Paenarthrobacter nicotinovorans xdh gene Proteins 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 150000002333 glycines Chemical class 0.000 description 4
- 230000029226 lipidation Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 240000005220 Bischofia javanica Species 0.000 description 3
- 235000010893 Bischofia javanica Nutrition 0.000 description 3
- 101000947616 Enterobacteria phage PRD1 Putative uncharacterized 4.5 kDa protein in genes IX-XX intergenic region Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000020897 Formins Human genes 0.000 description 3
- 108091022623 Formins Proteins 0.000 description 3
- LSPKYLAFTPBWIL-BYPYZUCNSA-N Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(O)=O LSPKYLAFTPBWIL-BYPYZUCNSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000941045 Homo sapiens Cortactin-binding protein 2 Proteins 0.000 description 3
- 108010015268 Integration Host Factors Proteins 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 108010090127 Periplasmic Proteins Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
- 239000007330 chocolate agar Substances 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 229940016590 sarkosyl Drugs 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 101150101515 tbpl2 gene Proteins 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- POSZUTFLHGNLHX-KSBRXOFISA-N tris maleate Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)\C=C/C(O)=O POSZUTFLHGNLHX-KSBRXOFISA-N 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SGPKEYSZPHMVNI-UHFFFAOYSA-N 2-bromo-1-(2-hydroxyphenyl)ethanone Chemical compound OC1=CC=CC=C1C(=O)CBr SGPKEYSZPHMVNI-UHFFFAOYSA-N 0.000 description 2
- 101710115267 ATP synthase protein MI25 Proteins 0.000 description 2
- 101100389816 Amycolatopsis orientalis evaA gene Proteins 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 231100000699 Bacterial toxin Toxicity 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 101000952186 Escherichia coli (strain K12) Membrane-bound lytic murein transglycosylase B Proteins 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 108010002231 IgA-specific serine endopeptidase Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 241000588653 Neisseria Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000010912 Transferrin-Binding Proteins Human genes 0.000 description 2
- 108010062476 Transferrin-Binding Proteins Proteins 0.000 description 2
- 101000623262 Trypanosoma brucei brucei Uncharacterized 22 kDa protein in aldolase locus Proteins 0.000 description 2
- 101710134973 Uncharacterized 9.7 kDa protein in cox-rep intergenic region Proteins 0.000 description 2
- 241000204362 Xylella fastidiosa Species 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- -1 aromatic amino acid Chemical class 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 239000000688 bacterial toxin Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 108010002832 murein transglycosylase Proteins 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 229920001510 poly[2-(diisopropylamino)ethyl methacrylate] polymer Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- SGWFGVQCRDTUQN-UHFFFAOYSA-N (2-prop-2-ynoyloxy-3-prop-2-ynoylsulfanylpropyl) prop-2-ynoate Chemical compound C#CC(=O)OCC(OC(=O)C#C)CSC(=O)C#C SGWFGVQCRDTUQN-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102100033926 AP-3 complex subunit delta-1 Human genes 0.000 description 1
- 241000023308 Acca Species 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100022524 Alpha-1-antichymotrypsin Human genes 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 101710191332 Cytochrome P450 monooxygenase cloA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102100022878 Deoxyribonuclease-2-beta Human genes 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588700 Dickeya chrysanthemi Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 101001079277 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Ribosomal RNA large subunit methyltransferase J Proteins 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101100153048 Homo sapiens ACAA1 gene Proteins 0.000 description 1
- 101000779252 Homo sapiens AP-3 complex subunit delta-1 Proteins 0.000 description 1
- 101000678026 Homo sapiens Alpha-1-antichymotrypsin Proteins 0.000 description 1
- 101000856513 Homo sapiens Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Proteins 0.000 description 1
- 101000724418 Homo sapiens Neutral amino acid transporter B(0) Proteins 0.000 description 1
- 101000653510 Homo sapiens TATA box-binding protein-like 2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100025509 Inactive N-acetyllactosaminide alpha-1,3-galactosyltransferase Human genes 0.000 description 1
- 206010053198 Inappropriate antidiuretic hormone secretion Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 101150022636 MAFB gene Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000588772 Morganella morganii Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
- 102100022219 NF-kappa-B essential modulator Human genes 0.000 description 1
- 101710090077 NF-kappa-B essential modulator Proteins 0.000 description 1
- 229910017974 NH40H Inorganic materials 0.000 description 1
- 241000588654 Neisseria cinerea Species 0.000 description 1
- 241000588649 Neisseria lactamica Species 0.000 description 1
- 241000588677 Neisseria meningitidis serogroup B Species 0.000 description 1
- 101100226860 Neisseria meningitidis serogroup B (strain MC58) fbpA gene Proteins 0.000 description 1
- 101100459189 Neisseria meningitidis serogroup B (strain MC58) mutS gene Proteins 0.000 description 1
- 101100472531 Neisseria meningitidis serogroup B (strain MC58) rmuC gene Proteins 0.000 description 1
- 102100028267 Neutral amino acid transporter B(0) Human genes 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101150068419 ORF 1 gene Proteins 0.000 description 1
- 101000783443 Orgyia pseudotsugata multicapsid polyhedrosis virus Uncharacterized 19.4 kDa protein Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000588701 Pectobacterium carotovorum Species 0.000 description 1
- 101710202686 Penicillin-sensitive transpeptidase Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- WOUIMBGNEUWXQG-VKHMYHEASA-N Ser-Gly Chemical compound OC[C@H](N)C(=O)NCC(O)=O WOUIMBGNEUWXQG-VKHMYHEASA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 101000870438 Streptococcus gordonii UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase stabilizing protein GtfB Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101000946719 Synechococcus elongatus (strain PCC 7942 / FACHB-805) Carboxysome assembly protein CcmN Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 102100030631 TATA box-binding protein-like 2 Human genes 0.000 description 1
- 240000002871 Tectona grandis Species 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 101000645119 Vibrio campbellii (strain ATCC BAA-1116 / BB120) Nucleotide-binding protein VIBHAR_03667 Proteins 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- MIVSDYNOAUEJHI-UHFFFAOYSA-N acetyl(trimethyl)azanium Chemical compound CC(=O)[N+](C)(C)C MIVSDYNOAUEJHI-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 108010027597 alpha-chymotrypsin Proteins 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010961 commercial manufacture process Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 108010002712 deoxyribonuclease II Proteins 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000001516 effect on protein Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010055246 excisionase Proteins 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 150000002307 glutamic acids Chemical group 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229960000789 guanidine hydrochloride Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000004201 immune sera Anatomy 0.000 description 1
- 229940042743 immune sera Drugs 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 201000008284 inappropriate ADH syndrome Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 238000002348 laser-assisted direct imprint lithography Methods 0.000 description 1
- 238000007169 ligase reaction Methods 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229940076266 morganella morganii Drugs 0.000 description 1
- 229940051921 muramidase Drugs 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000001935 permeabilising effect Effects 0.000 description 1
- 108700010839 phage proteins Proteins 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000232 polyglycine polymer Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010845 search algorithm Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 108091085754 transglycosylase family Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0004695.3 | 2000-02-28 | ||
| GB0004695A GB0004695D0 (en) | 2000-02-28 | 2000-02-28 | Protein expression |
| GB0027675A GB0027675D0 (en) | 2000-11-13 | 2000-11-13 | Protein Expression |
| GB0027675.8 | 2000-11-13 | ||
| PCT/IB2001/000452 WO2001064922A2 (en) | 2000-02-28 | 2001-02-28 | Heterologous expression of neisserial proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001239488A1 AU2001239488A1 (en) | 2001-11-22 |
| AU2001239488B2 true AU2001239488B2 (en) | 2006-01-19 |
Family
ID=26243750
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001239488A Ceased AU2001239488B2 (en) | 2000-02-28 | 2001-02-28 | Heterologous expression of neisserial proteins |
| AU3947801A Pending AU3947801A (en) | 2000-02-28 | 2001-02-28 | Hybrid expression of neisserial proteins |
| AU3948801A Pending AU3948801A (en) | 2000-02-28 | 2001-02-28 | Heterologous expression of neisserial proteins |
| AU2001239478A Ceased AU2001239478B2 (en) | 2000-02-28 | 2001-02-28 | Hybrid expression of neisserial proteins |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU3947801A Pending AU3947801A (en) | 2000-02-28 | 2001-02-28 | Hybrid expression of neisserial proteins |
| AU3948801A Pending AU3948801A (en) | 2000-02-28 | 2001-02-28 | Heterologous expression of neisserial proteins |
| AU2001239478A Ceased AU2001239478B2 (en) | 2000-02-28 | 2001-02-28 | Hybrid expression of neisserial proteins |
Country Status (19)
| Country | Link |
|---|---|
| US (9) | US7803387B2 (enExample) |
| EP (6) | EP2270031A3 (enExample) |
| JP (8) | JP4763210B2 (enExample) |
| CN (7) | CN1800385B (enExample) |
| AT (3) | ATE387502T1 (enExample) |
| AU (4) | AU2001239488B2 (enExample) |
| BR (2) | BR0108713A (enExample) |
| CA (5) | CA2744921C (enExample) |
| CY (6) | CY1106532T1 (enExample) |
| DE (3) | DE60144353D1 (enExample) |
| DK (4) | DK1947187T5 (enExample) |
| ES (5) | ES2299476T3 (enExample) |
| LU (1) | LU92240I2 (enExample) |
| MX (2) | MXPA02008313A (enExample) |
| NL (1) | NL300605I2 (enExample) |
| NZ (2) | NZ521396A (enExample) |
| PT (4) | PT1790660E (enExample) |
| RU (2) | RU2304617C2 (enExample) |
| WO (2) | WO2001064920A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008234959B2 (en) * | 2001-09-06 | 2012-05-17 | Novartis Vaccines And Diagnostics S.R.L. | Hybrid and tandem expression of Neisserial proteins |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001500738A (ja) | 1996-09-17 | 2001-01-23 | カイロン コーポレイション | 細胞内疾患を処置するための組成物および方法 |
| SG152917A1 (en) * | 1998-01-14 | 2009-06-29 | Chiron Srl | Neisseria meningitidis antigens |
| EP2261350A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
| ES2228454T3 (es) * | 1999-02-26 | 2005-04-16 | Chiron S.R.L. | Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg. |
| US7368261B1 (en) | 1999-04-30 | 2008-05-06 | Novartis Vaccines And Diagnostics Srl | Conserved Neisserial antigens |
| GB9911683D0 (en) * | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| EP2258851A1 (en) * | 1999-05-19 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Combination neisserial compositions |
| EP1801219B1 (en) | 1999-10-29 | 2015-10-14 | GlaxoSmithKline Biologicals S.A. | Neisserial antigenic peptides |
| GB9928196D0 (en) | 1999-11-29 | 2000-01-26 | Chiron Spa | Combinations of B, C and other antigens |
| ATE476988T1 (de) | 2000-01-17 | 2010-08-15 | Novartis Vaccines & Diagnostic | Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält |
| PT1790660E (pt) | 2000-02-28 | 2012-09-17 | Novartis Vaccines & Diagnostic | Expressão heteróloga de proteínas de neisseria |
| RU2322451C2 (ru) * | 2001-04-17 | 2008-04-20 | Новартис Вэксинс Энд Диагностикс, Инк. | Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител |
| GB0115176D0 (en) | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| US6928463B1 (en) * | 2001-07-06 | 2005-08-09 | Nortel Networks Limited | Broadband content delivery via personal content tunnel |
| GB0118249D0 (en) | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| BR0211494A (pt) * | 2001-07-27 | 2004-08-17 | Chiron Srl | Adesinas de meningococo nada, app e orf 40 |
| AU2014201962B2 (en) * | 2001-09-06 | 2016-06-09 | Glaxosmithkline Vaccines S.R.L. | Hybrid and tandem expression of Neisserial proteins |
| US7838015B2 (en) | 2001-10-03 | 2010-11-23 | Novartis Vaccines And Diagnostics, Inc. | Adjuvanted meningococcus compositions |
| AR045702A1 (es) | 2001-10-03 | 2005-11-09 | Chiron Corp | Composiciones de adyuvantes. |
| CN100354297C (zh) * | 2001-10-03 | 2007-12-12 | 希龙公司 | 辅助的脑膜炎球菌组合物 |
| MX339524B (es) * | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| NZ587398A (en) | 2002-08-02 | 2012-03-30 | Glaxosmithkline Biolog Sa | Neisserial bleb preparations and vaccines comprising them |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| HUE031886T2 (en) * | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| SI1556477T1 (sl) | 2002-11-01 | 2017-12-29 | Glaxosmithkline Biologicals S.A. | Sušilni postopek |
| DE60332477D1 (de) | 2002-11-15 | 2010-06-17 | Novartis Vaccines & Diagnostic | Unerwartete oberflächenproteine in neisseria meningitidis |
| GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| PT2191844E (pt) | 2003-01-30 | 2014-06-04 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| ATE516306T1 (de) | 2003-08-13 | 2011-07-15 | Novartis Vaccines & Diagnostic | Verbessertes verfahren zur reinigung von tfpi und tfpi-analogen |
| RU2378010C2 (ru) | 2003-10-02 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс С.Р.Л. | Жидкие вакцины для множественных серогрупп менингококков |
| GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| GB0408977D0 (en) | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0409748D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
| GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| DK1858920T3 (en) | 2005-02-18 | 2016-02-29 | Glaxosmithkline Biolog Sa | PROTEINS AND NUCLEIC ACIDS FROM MENINGITIS / SEPSIS-ASSOCIATED ESCHERICHIA COLI |
| JP2008530245A (ja) | 2005-02-18 | 2008-08-07 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド | 尿路病原性菌株由来の抗原 |
| CN100475965C (zh) * | 2005-07-22 | 2009-04-08 | 上海高科联合生物技术研发有限公司 | 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法 |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| US20110008279A1 (en) * | 2005-12-06 | 2011-01-13 | Vega Masignani | Methods and Compositions Relating to Adhesins as Adjuvants |
| EP2586790A3 (en) | 2006-08-16 | 2013-08-14 | Novartis AG | Immunogens from uropathogenic Escherichia coli |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| GB0713880D0 (en) | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| SI2200642T1 (sl) | 2007-10-19 | 2012-06-29 | Novartis Ag | Formulacije meningokoknega cepiva |
| NZ587382A (en) | 2008-02-21 | 2012-01-12 | Novartis Ag | Meningococcal fhbp polypeptides |
| SI2268618T1 (sl) | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
| RU2360926C9 (ru) * | 2008-03-17 | 2009-09-10 | Всеволод Иванович Киселев | ГИБРИДНЫЙ БЕЛОК CFP10-ESAT6, ИНДУЦИРУЮЩИЙ РЕАКЦИЮ ГИПЕРЧУВСТВИТЕЛЬНОСТИ ЗАМЕДЛЕННОГО ТИПА В ОТНОШЕНИИ M.Tuberculosis, КОДИРУЮЩАЯ ЕГО ХИМЕРНАЯ НУКЛЕИНОВАЯ КИСЛОТА И РЕКОМБИНАНТНЫЙ ПЛАЗМИДНЫЙ ЭКСПРЕССИРУЮЩИЙ ВЕКТОР, ЕЕ СОДЕРЖАЩИЙ, СПОСОБ ПОЛУЧЕНИЯ ГИБРИДНОГО БЕЛКА И ДОЗИРОВАННАЯ ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ ВНУТРИКОЖНОЙ ИНЪЕКЦИИ НА ЕГО ОСНОВЕ |
| US20100105875A1 (en) * | 2008-06-09 | 2010-04-29 | Maria Scarselli | Antibodies against neisserial factor H binding protein |
| JP5487463B2 (ja) | 2008-08-08 | 2014-05-07 | 独立行政法人産業技術総合研究所 | 非拡散植物ウイルスベクター |
| ES2797504T3 (es) | 2009-03-24 | 2020-12-02 | Glaxosmithkline Biologicals Sa | Proteína de enlace del factor H meningocócico utilizada como adyuvante |
| CN102762226A (zh) | 2009-06-10 | 2012-10-31 | 诺华有限公司 | 含苯并萘啶的疫苗 |
| WO2011008400A2 (en) | 2009-06-16 | 2011-01-20 | Novartis Ag | High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays |
| AU2010288240B2 (en) | 2009-08-27 | 2014-03-27 | Novartis Ag | Hybrid polypeptides including meningococcal fHBP sequences |
| MX2012002723A (es) | 2009-09-02 | 2012-04-11 | Novartis Ag | Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll. |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| EP2483390A2 (en) | 2009-09-30 | 2012-08-08 | Novartis AG | Expression of meningococcal fhbp polypeptides |
| CA2779816A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| BR112012014624A8 (pt) | 2009-12-15 | 2017-12-26 | Novartis Ag | suspensão homogênea de compostos de imunopotenciação e usos dos destes |
| US8808703B2 (en) | 2010-03-23 | 2014-08-19 | Tom Yao-Hsiang Wu | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc |
| WO2011161653A1 (en) | 2010-06-25 | 2011-12-29 | Novartis Ag | Combinations of meningococcal factor h binding proteins |
| SI2608805T2 (sl) | 2010-08-23 | 2025-09-30 | Wyeth Llc | Stabilne formulacije antigenov rLP2086 neisserie meningitidis |
| BR112013005329A2 (pt) | 2010-09-10 | 2017-05-02 | Wyeth Llc | variantes não lipidadas de antígenos orf2086 de neisseria meningitidis |
| BR112013005626B1 (pt) | 2010-09-10 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição |
| GB201102090D0 (en) * | 2011-02-08 | 2011-03-23 | Univ Sheffield | Antigenic polypeptide |
| CN103906534A (zh) | 2011-08-31 | 2014-07-02 | 奥克兰儿童医院及研究中心 | 在奈瑟氏菌中推动抗原表达的工程化序列及使用方法 |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| MX2018011291A (es) | 2012-03-09 | 2023-01-31 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| NZ630133A (en) | 2012-06-14 | 2016-10-28 | Novartis Ag | Vaccines for serogroup x meningococcus |
| CA2875391A1 (en) | 2012-07-27 | 2014-01-30 | Institut National De La Sante Et De La Recherche Medicale | Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia |
| WO2014084432A1 (ko) * | 2012-11-30 | 2014-06-05 | 경상대학교 산학협력단 | 헬리코박터 파일로리 발현 벡터 |
| WO2014136064A2 (en) | 2013-03-08 | 2014-09-12 | Pfizer Inc. | Immunogenic fusion polypeptides |
| BR112016004463A2 (pt) | 2013-09-08 | 2017-10-17 | Pfizer | composições de neisseria meningitidis e métodos das mesmas |
| JP6786394B2 (ja) | 2014-02-28 | 2020-11-18 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 改変髄膜炎菌ｆＨｂｐポリペプチド |
| CN112851768A (zh) | 2014-07-23 | 2021-05-28 | 奥克兰儿童医院及研究中心 | 因子h结合蛋白变体及其使用方法 |
| WO2016132294A1 (en) | 2015-02-19 | 2016-08-25 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| GB201522153D0 (en) | 2015-12-15 | 2016-01-27 | Univ Southampton | Meningococcal infection and modified neisseria lactamica |
| EP3506933A2 (en) | 2016-09-02 | 2019-07-10 | GlaxoSmithKline Biologicals SA | Vaccines for neisseria gonorrhoeae |
| EP3312192B1 (en) * | 2016-10-24 | 2023-02-22 | BiOMVis Srl | Immunogenic compositions containing bacterial outer membrane vesicles |
| AU2018215585B2 (en) | 2017-01-31 | 2022-03-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| CN110516550B (zh) * | 2019-07-26 | 2022-07-05 | 电子科技大学 | 一种基于fpga的车道线实时检测方法 |
| MX2022003682A (es) | 2019-09-27 | 2022-04-25 | Pfizer | Composiciones de neisseria meningitidis y metodos de las mismas. |
| CN115348968A (zh) * | 2019-11-25 | 2022-11-15 | 格里菲斯大学 | 针对淋球菌感染的免疫原性蛋白 |
| US12053516B2 (en) | 2021-02-19 | 2024-08-06 | Sanofi Pasteur Inc. | Meningococcal B recombinant vaccine |
| GB202208089D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| GB202208093D0 (en) | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| TW202423477A (zh) | 2022-08-03 | 2024-06-16 | 美商賽諾菲巴斯德公司 | 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2720408A1 (fr) * | 1994-05-31 | 1995-12-01 | Pasteur Merieux Serums Vacc | Fragments Tbp2 de Neisseria meningitidis. |
| WO1999024578A2 (en) * | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
| AU4309600A (en) * | 1999-04-30 | 2000-11-17 | Chiron S.R.L. | Conserved neisserial antigens |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4239749A (en) * | 1979-09-27 | 1980-12-16 | United States Of America | Neisseria gonorrhoeae vaccine |
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| US5288641A (en) * | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| EP0273116A3 (en) | 1986-10-09 | 1990-05-02 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Gonococcal and meningococcal polypeptides, vaccines and diagnostics |
| GB8702816D0 (en) | 1987-02-07 | 1987-03-11 | Al Sumidaie A M K | Obtaining retrovirus-containing fraction |
| US5270176A (en) * | 1987-11-20 | 1993-12-14 | Hoechst Aktiengesellschaft | Method for the selective cleavage of fusion proteins with lysostaphin |
| CA1340506C (en) * | 1987-11-24 | 1999-04-20 | Nicholas H. Carbonetti | Production of gonorrheal pi proteins and vaccines |
| CN1038306A (zh) | 1988-03-21 | 1989-12-27 | 维吉恩公司 | 重组反转录病毒 |
| US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
| US5422120A (en) * | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| AP129A (en) | 1988-06-03 | 1991-04-17 | Smithkline Biologicals S A | Expression of retrovirus gag protein eukaryotic cells |
| WO1990006696A2 (en) | 1988-12-19 | 1990-06-28 | Praxis Biologics, Inc. | Meningococcal class 1 outer-membrane protein vaccine |
| NL8803111A (nl) | 1988-12-19 | 1990-07-16 | Nederlanden Staat | Multivalent meningococcen klasse i buitenmembraaneiwit vaccin. |
| JP3250802B2 (ja) | 1989-03-21 | 2002-01-28 | バイカル・インコーポレイテッド | 脊椎動物における外因性ポリヌクレオチド配列の発現 |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8919607D0 (en) | 1989-08-30 | 1989-10-11 | Wellcome Found | Novel entities for cancer therapy |
| CU22302A1 (es) * | 1990-09-07 | 1995-01-31 | Cigb | Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales |
| IE912559A1 (en) | 1990-07-19 | 1992-01-29 | Merck & Co Inc | The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same |
| EP0549723A1 (en) | 1990-09-21 | 1993-07-07 | Chiron Corporation | Packaging cells |
| US5965424A (en) * | 1991-01-11 | 1999-10-12 | Boehringer Mannheim Gmbh | Methods for making neisseria or hemophilus IgA protease and DNA encoding the proteases |
| DE69227898T2 (de) * | 1991-03-14 | 1999-05-12 | Imclone Systems, Inc., New York, N.Y. | Rekombinante hybride porinepitope |
| FR2681786A1 (fr) | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
| NZ244306A (en) | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
| IL103059A0 (en) | 1991-09-30 | 1993-02-21 | Boehringer Ingelheim Int | Conjugates for introducing nucleic acid into higher eucaryotic cells |
| US6100380A (en) * | 1991-10-28 | 2000-08-08 | Cytran, Inc. | Immunomodulating peptides and methods of use |
| EP0625049A4 (en) | 1992-01-23 | 1995-07-12 | Vical Inc | EX VIVO GENTRANSFER. |
| FR2692592B1 (fr) * | 1992-06-19 | 1995-03-31 | Pasteur Merieux Serums Vacc | Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant. |
| EP1329519B1 (en) * | 1992-07-07 | 2005-12-28 | Fuso Pharmaceutical Industries Ltd. | Probe for diagnosing infectious disease arising from Staphylococcus aureus |
| US6592873B1 (en) | 1992-10-30 | 2003-07-15 | Iowa State University Research Foundation, Inc. | Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids |
| CA2132742C (en) * | 1993-01-23 | 2000-04-18 | Carmen Vela Olmo | Synthetic peptides and vaccines against parvovirus |
| US5439808A (en) * | 1993-07-23 | 1995-08-08 | North American Vaccine, Inc. | Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis |
| CA2167938A1 (en) * | 1993-07-30 | 1995-02-09 | Christopher Elkins | Production of gonorrheal pi proteins and vaccines in e. coli and salmonella |
| US5914254A (en) * | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US5510264A (en) | 1993-09-28 | 1996-04-23 | Insight Biotech Inc. | Antibodies which bind meningitis related homologous antigenic sequences |
| KR100241300B1 (ko) | 1993-11-16 | 2000-03-02 | Sheldon A. Schaffer | 활성물질의 조절된 방출성을 갖는 소포 |
| AU2585395A (en) | 1994-05-09 | 1995-11-29 | Chiron Corporation | Retroviral vectors having a reduced recombination rate |
| US6245337B1 (en) | 1994-08-25 | 2001-06-12 | Washington University | Haemophilus adherence and penetration proteins |
| IL117483A (en) | 1995-03-17 | 2008-03-20 | Bernard Brodeur | MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K. |
| US5646259A (en) | 1995-03-24 | 1997-07-08 | St. Louis University | DNA encoding haemophilus adhesion proteins |
| US6265567B1 (en) | 1995-04-07 | 2001-07-24 | University Of North Carolina At Chapel Hill | Isolated FrpB nucleic acid molecule |
| CA2704354A1 (en) * | 1995-06-07 | 1996-12-19 | Connaught Laboratories, Inc. | Expression of lipoproteins |
| DE19534579C2 (de) | 1995-09-18 | 2000-06-08 | Max Planck Gesellschaft | Nucleinsäure-Moleküle codierend Proteine, die die Adhäsion von Neisseria-Zellen an humane Zellen vermitteln |
| ES2217325T5 (es) | 1995-09-18 | 2009-04-01 | United States Army Medical Research Materiel Command (Usamrmc) | Metodos mejorados para la produccion de vacunas de subunidades multivalentes de proteosomas acomplejados no covalentemente. |
| FR2739624B1 (fr) * | 1995-10-10 | 1997-12-05 | Pasteur Merieux Serums Vacc | Nouvelle sous-unite tbp2 de neisseria meningitidis |
| ZA9610456B (en) * | 1995-12-20 | 1997-06-20 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
| WO1997028273A1 (en) * | 1996-02-01 | 1997-08-07 | North American Vaccine, Inc. | Expression of group b neisseria meningitidis outer membrane (mb3) protein from yeast and vaccines |
| US6083499A (en) * | 1996-04-19 | 2000-07-04 | Mycogen Corporation | Pesticidal toxins |
| WO1998017805A2 (en) | 1996-10-24 | 1998-04-30 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, c/o Centers for Disease Control and Prevention, Technology Transfer Office | Invasion associated genes from neisseria meningitidis serogroup b |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| CN1159441C (zh) | 1996-12-20 | 2004-07-28 | 德克萨斯州大学系统董事会 | 粘膜炎莫拉菌的uspa1和uspa2抗原 |
| US6017531A (en) | 1997-06-02 | 2000-01-25 | W. R. Grace & Co. | Hydrophilic composition containing protease produced by Vibrio |
| US6583275B1 (en) * | 1997-07-02 | 2003-06-24 | Genome Therapeutics Corporation | Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics |
| US6914131B1 (en) * | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
| GB9726398D0 (en) | 1997-12-12 | 1998-02-11 | Isis Innovation | Polypeptide and coding sequences |
| SG152917A1 (en) * | 1998-01-14 | 2009-06-29 | Chiron Srl | Neisseria meningitidis antigens |
| ATE445015T1 (de) * | 1998-02-03 | 2009-10-15 | Ct Disease Contr & Prevention | Verfahren zur herstellung rekombinanter, lipid- modifizierter psaa proteine und deren verwendung |
| WO1999041230A1 (en) * | 1998-02-11 | 1999-08-19 | Eli Lilly And Company | Processes and intermediates useful to make antifolates |
| GB9808734D0 (en) | 1998-04-23 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| GB9808866D0 (en) * | 1998-04-24 | 1998-06-24 | Smithkline Beecham Biolog | Novel compounds |
| US6150502A (en) * | 1998-04-29 | 2000-11-21 | Genesis Research & Development Corporation Limited | Polypeptides expressed in skin cells |
| US6615024B1 (en) * | 1998-05-01 | 2003-09-02 | Arraycomm, Inc. | Method and apparatus for determining signatures for calibrating a communication station having an antenna array |
| US20070026021A1 (en) * | 1998-05-01 | 2007-02-01 | Chiron S.R.I. | Neisseria meningitidis antigens and compositions |
| EP2261350A3 (en) * | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| US5990085A (en) * | 1998-05-04 | 1999-11-23 | Michigan State University | Inhibin-HBc fusion protein |
| GB9810276D0 (en) | 1998-05-13 | 1998-07-15 | Smithkline Beecham Biolog | Novel compounds |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| MXPA01003557A (es) * | 1998-10-09 | 2004-04-05 | Chiron Corp | Secuencias genomicas de neisseria y metodos para su uso. |
| AU2289000A (en) | 1999-01-15 | 2000-08-01 | Smithkline Beecham Biologicals (Sa) | (neisseria meningitidis) polypeptide basb052 |
| AU2292800A (en) | 1999-01-22 | 2000-08-07 | Smithkline Beecham Biologicals (Sa) | Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides andprotective antibodies |
| GB9902084D0 (en) | 1999-01-29 | 1999-03-24 | Smithkline Beecham Biolog | Novel compounds |
| ES2228454T3 (es) * | 1999-02-26 | 2005-04-16 | Chiron S.R.L. | Mejora de la actividad bacteriana de antigenos de neisseria con oligonucleotidos que contienen motivos cg. |
| EP1185691B1 (en) | 1999-04-30 | 2009-04-29 | Novartis Vaccines and Diagnostics, Inc. | Neisseria genomic sequences and methods of their use |
| GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
| EP2258851A1 (en) * | 1999-05-19 | 2010-12-08 | Novartis Vaccines and Diagnostics S.r.l. | Combination neisserial compositions |
| GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
| EP1801219B1 (en) * | 1999-10-29 | 2015-10-14 | GlaxoSmithKline Biologicals S.A. | Neisserial antigenic peptides |
| DK1741784T3 (da) * | 1999-11-29 | 2010-05-25 | Novartis Vaccines & Diagnostic | 85kDa-antigen fra neisseria |
| GB9928676D0 (en) | 1999-12-03 | 2000-02-02 | Provalis Uk Ltd | Pseudomonas aeruginosa antigens |
| US20010031268A1 (en) * | 1999-12-17 | 2001-10-18 | Baldwin Thomas John | Antigen preparations |
| ATE476988T1 (de) | 2000-01-17 | 2010-08-15 | Novartis Vaccines & Diagnostic | Membranvesikel (omv) impfstoff, der n. meningitidis serogruppe b membranproteine enthält |
| WO2001055182A1 (en) | 2000-01-25 | 2001-08-02 | The University Of Queensland | PROTEINS COMPRISING CONSERVED REGIONS OF NEISSERIA MENINGITIDIS SURFACE ANTIGEN NhhA |
| PT1790660E (pt) * | 2000-02-28 | 2012-09-17 | Novartis Vaccines & Diagnostic | Expressão heteróloga de proteínas de neisseria |
| EP1278854A2 (en) | 2000-04-21 | 2003-01-29 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of acne vulgaris |
| EP1297005B1 (en) | 2000-07-03 | 2009-08-26 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia pneumoniae |
| GB0017149D0 (en) | 2000-07-12 | 2000-08-30 | Chiron Spa | Helicobacter pylori mutants |
| GB0103170D0 (en) | 2001-02-08 | 2001-03-28 | Smithkline Beecham Biolog | Vaccine composition |
| US20040073294A1 (en) * | 2002-09-20 | 2004-04-15 | Conor Medsystems, Inc. | Method and apparatus for loading a beneficial agent into an expandable medical device |
| GB0103424D0 (en) * | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| GB0118249D0 (en) * | 2001-07-26 | 2001-09-19 | Chiron Spa | Histidine vaccines |
| EP1409013B1 (en) | 2001-07-26 | 2009-11-18 | Novartis Vaccines and Diagnostics S.r.l. | Vaccines comprising aluminium adjuvants and histidine |
| BR0211494A (pt) | 2001-07-27 | 2004-08-17 | Chiron Srl | Adesinas de meningococo nada, app e orf 40 |
| GB0121591D0 (en) * | 2001-09-06 | 2001-10-24 | Chiron Spa | Hybrid and tandem expression of neisserial proteins |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| GB0129007D0 (en) * | 2001-12-04 | 2002-01-23 | Chiron Spa | Adjuvanted antigenic meningococcal compositions |
| NZ587398A (en) * | 2002-08-02 | 2012-03-30 | Glaxosmithkline Biolog Sa | Neisserial bleb preparations and vaccines comprising them |
| US7785608B2 (en) * | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| HUE031886T2 (en) * | 2002-10-11 | 2017-08-28 | Glaxosmithkline Biologicals Sa | Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines |
| GB0227346D0 (en) * | 2002-11-22 | 2002-12-31 | Chiron Spa | 741 |
| EP1590459A2 (en) | 2003-01-15 | 2005-11-02 | Wyeth Holdings Corporation | Methods for increasing neisseria protein expression and compositions thereof |
| PT2191844E (pt) * | 2003-01-30 | 2014-06-04 | Novartis Ag | Vacinas injetáveis contra múltiplos serogrupos meningocócicos |
| MXPA05011110A (es) | 2003-04-16 | 2006-01-24 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos. |
| GB0315021D0 (en) * | 2003-06-26 | 2003-07-30 | Chiron Srl | Immunogenic gonococcal compositions |
| GB0323103D0 (en) * | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
| RU2378010C2 (ru) * | 2003-10-02 | 2010-01-10 | Новартис Вэксинес Энд Дайэгностикс С.Р.Л. | Жидкие вакцины для множественных серогрупп менингококков |
| GB0408977D0 (en) * | 2004-04-22 | 2004-05-26 | Chiron Srl | Immunising against meningococcal serogroup Y using proteins |
| GB0409748D0 (en) * | 2004-04-30 | 2004-06-09 | Chiron Srl | Lactoferrin cleavage |
| GB0410866D0 (en) * | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| GB0419408D0 (en) * | 2004-09-01 | 2004-10-06 | Chiron Srl | 741 chimeric polypeptides |
| CA2590974C (en) | 2005-01-27 | 2017-10-03 | Children's Hospital & Research Center At Oakland | Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| GB0524066D0 (en) | 2005-11-25 | 2006-01-04 | Chiron Srl | 741 ii |
| DK2004225T3 (da) | 2006-03-22 | 2012-08-06 | Novartis Ag | Programmer for vaccination med meningocockonjugater |
| TW200806315A (en) | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
| US8039007B2 (en) * | 2006-06-29 | 2011-10-18 | J. Craig Venter Institute, Inc. | Polypeptides from Neisseria meningitidis |
| AR064642A1 (es) * | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| WO2008125985A2 (en) | 2007-04-11 | 2008-10-23 | Novartis Ag | Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes |
| NZ581367A (en) | 2007-06-04 | 2012-05-25 | Novartis Ag | Formulation of meningitis vaccines containing haemophilus influenzae and neisseria meningitidis |
| NZ587382A (en) | 2008-02-21 | 2012-01-12 | Novartis Ag | Meningococcal fhbp polypeptides |
| SI2268618T1 (sl) * | 2008-03-03 | 2015-09-30 | Novartis Ag | Spojine in sestavki kot modulatorji aktivnosti TLR |
| US9511131B2 (en) | 2008-03-10 | 2016-12-06 | Children's Hospital & Research Center Oakland | Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use |
| CA2733943A1 (en) | 2008-09-03 | 2010-03-11 | Children's Hospital & Research Center At Oakland | Peptides presenting an epitope of an a domain of factor h binding protein and methods of use |
| IT1394288B1 (it) | 2008-09-12 | 2012-06-06 | Novartis Vaccines & Diagnostic | Immunogeni di proteine che legano il fattore h. |
| GB0819633D0 (en) | 2008-10-25 | 2008-12-03 | Isis Innovation | Composition |
| ES2797504T3 (es) * | 2009-03-24 | 2020-12-02 | Glaxosmithkline Biologicals Sa | Proteína de enlace del factor H meningocócico utilizada como adyuvante |
| CN105999275A (zh) * | 2010-09-01 | 2016-10-12 | 诺华有限公司 | 免疫增强剂吸附不溶性金属离子 |
| US9057716B2 (en) * | 2010-09-04 | 2015-06-16 | Novartis Ag | Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines |
| BR112013005626B1 (pt) * | 2010-09-10 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição |
| CA2835630A1 (en) * | 2011-05-11 | 2012-11-15 | Richard Malley | Modified biotin-binding protein, fusion proteins thereof and applications |
| US9184727B2 (en) * | 2012-06-11 | 2015-11-10 | Phonon Corporation | SAW device and method for post-seal frequency trimming |
-
2001
- 2001-02-28 PT PT06076718T patent/PT1790660E/pt unknown
- 2001-02-28 PT PT08075111T patent/PT1947187E/pt unknown
- 2001-02-28 CN CN200510116305XA patent/CN1800385B/zh not_active Expired - Fee Related
- 2001-02-28 MX MXPA02008313A patent/MXPA02008313A/es active IP Right Grant
- 2001-02-28 EP EP10178655A patent/EP2270031A3/en not_active Ceased
- 2001-02-28 US US10/220,481 patent/US7803387B2/en not_active Expired - Fee Related
- 2001-02-28 PT PT01914098T patent/PT1261723E/pt unknown
- 2001-02-28 CA CA2744921A patent/CA2744921C/en not_active Expired - Fee Related
- 2001-02-28 AU AU2001239488A patent/AU2001239488B2/en not_active Ceased
- 2001-02-28 JP JP2001563611A patent/JP4763210B2/ja not_active Expired - Fee Related
- 2001-02-28 AU AU3947801A patent/AU3947801A/xx active Pending
- 2001-02-28 RU RU2002125880/13A patent/RU2304617C2/ru not_active IP Right Cessation
- 2001-02-28 WO PCT/IB2001/000420 patent/WO2001064920A2/en not_active Ceased
- 2001-02-28 CN CNB018087388A patent/CN100339482C/zh not_active Expired - Fee Related
- 2001-02-28 DE DE60144353T patent/DE60144353D1/de not_active Expired - Lifetime
- 2001-02-28 AT AT01914098T patent/ATE387502T1/de active
- 2001-02-28 AU AU3948801A patent/AU3948801A/xx active Pending
- 2001-02-28 CN CNB2003101028453A patent/CN100473663C/zh not_active Expired - Fee Related
- 2001-02-28 ES ES01914098T patent/ES2299476T3/es not_active Expired - Lifetime
- 2001-02-28 AT AT01914109T patent/ATE352631T1/de active
- 2001-02-28 DK DK08075111.8T patent/DK1947187T5/da active
- 2001-02-28 DK DK10178586.3T patent/DK2270030T3/da active
- 2001-02-28 EP EP01914098A patent/EP1261723B1/en not_active Expired - Lifetime
- 2001-02-28 ES ES01914109T patent/ES2281409T3/es not_active Expired - Lifetime
- 2001-02-28 EP EP08075111A patent/EP1947187B9/en not_active Expired - Lifetime
- 2001-02-28 EP EP06076718A patent/EP1790660B1/en not_active Expired - Lifetime
- 2001-02-28 JP JP2001563609A patent/JP4846160B2/ja not_active Expired - Fee Related
- 2001-02-28 DE DE60132978T patent/DE60132978T2/de not_active Expired - Lifetime
- 2001-02-28 ES ES06076718T patent/ES2391153T3/es not_active Expired - Lifetime
- 2001-02-28 BR BR0108713-4A patent/BR0108713A/pt not_active IP Right Cessation
- 2001-02-28 PT PT10178586T patent/PT2270030E/pt unknown
- 2001-02-28 DK DK01914098T patent/DK1261723T3/da active
- 2001-02-28 DK DK06076718.3T patent/DK1790660T3/da active
- 2001-02-28 AU AU2001239478A patent/AU2001239478B2/en not_active Ceased
- 2001-02-28 EP EP10178586A patent/EP2270030B1/en not_active Expired - Lifetime
- 2001-02-28 CN CNB2003101036036A patent/CN100334214C/zh not_active Expired - Fee Related
- 2001-02-28 AT AT08075111T patent/ATE503837T1/de active
- 2001-02-28 EP EP01914109A patent/EP1259627B1/en not_active Expired - Lifetime
- 2001-02-28 ES ES08075111T patent/ES2360746T3/es not_active Expired - Lifetime
- 2001-02-28 CA CA2400562A patent/CA2400562C/en not_active Expired - Fee Related
- 2001-02-28 NZ NZ521396A patent/NZ521396A/xx not_active IP Right Cessation
- 2001-02-28 CA CA2689666A patent/CA2689666C/en not_active Expired - Fee Related
- 2001-02-28 CN CN2007101391568A patent/CN101139590B/zh not_active Expired - Fee Related
- 2001-02-28 ES ES10178586T patent/ES2386534T3/es not_active Expired - Lifetime
- 2001-02-28 WO PCT/IB2001/000452 patent/WO2001064922A2/en not_active Ceased
- 2001-02-28 BR BR0108711-8A patent/BR0108711A/pt not_active Application Discontinuation
- 2001-02-28 NZ NZ521531A patent/NZ521531A/en not_active IP Right Cessation
- 2001-02-28 CN CNB018087507A patent/CN1201011C/zh not_active Expired - Fee Related
- 2001-02-28 RU RU2002125882/13A patent/RU2299906C2/ru not_active IP Right Cessation
- 2001-02-28 US US10/220,480 patent/US20040092711A1/en not_active Abandoned
- 2001-02-28 CN CN2010101656630A patent/CN101906413A/zh active Pending
- 2001-02-28 MX MXPA02008314A patent/MXPA02008314A/es active IP Right Grant
- 2001-02-28 CA CA2400570A patent/CA2400570C/en not_active Expired - Fee Related
- 2001-02-28 DE DE60126249T patent/DE60126249T2/de not_active Expired - Lifetime
- 2001-02-28 CA CA2875231A patent/CA2875231A1/en not_active Abandoned
-
2005
- 2005-02-25 US US11/067,260 patent/US9267163B2/en not_active Expired - Fee Related
-
2007
- 2007-04-19 CY CY20071100540T patent/CY1106532T1/el unknown
-
2008
- 2008-04-30 CY CY20081100464T patent/CY1107447T1/el unknown
-
2010
- 2010-06-28 US US12/825,210 patent/US8114960B2/en not_active Expired - Fee Related
- 2010-12-24 JP JP2010288968A patent/JP5346004B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-12 JP JP2011004414A patent/JP2011101657A/ja active Pending
- 2011-06-27 CY CY20111100604T patent/CY1111591T1/el unknown
- 2011-12-29 US US13/340,549 patent/US8703914B2/en not_active Expired - Fee Related
-
2012
- 2012-08-13 CY CY20121100728T patent/CY1113032T1/el unknown
- 2012-09-19 CY CY20121100861T patent/CY1113477T1/el unknown
- 2012-09-27 JP JP2012214120A patent/JP2013005816A/ja not_active Withdrawn
-
2013
- 2013-07-03 CY CY2013025C patent/CY2013025I2/el unknown
- 2013-07-04 LU LU92240C patent/LU92240I2/fr unknown
- 2013-07-15 NL NL300605C patent/NL300605I2/nl unknown
- 2013-09-18 JP JP2013192617A patent/JP5941027B2/ja not_active Expired - Fee Related
-
2014
- 2014-03-18 JP JP2014054817A patent/JP2014121333A/ja active Pending
- 2014-04-03 US US14/244,806 patent/US20140294885A1/en not_active Abandoned
- 2014-07-31 US US14/448,792 patent/US9150898B2/en not_active Expired - Fee Related
-
2016
- 2016-04-11 JP JP2016078708A patent/JP2016128520A/ja active Pending
- 2016-12-02 US US15/368,435 patent/US20170080077A1/en not_active Abandoned
- 2016-12-02 US US15/368,429 patent/US20170080076A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2720408A1 (fr) * | 1994-05-31 | 1995-12-01 | Pasteur Merieux Serums Vacc | Fragments Tbp2 de Neisseria meningitidis. |
| WO1999024578A2 (en) * | 1997-11-06 | 1999-05-20 | Chiron S.P.A. | Neisserial antigens |
| AU4309600A (en) * | 1999-04-30 | 2000-11-17 | Chiron S.R.L. | Conserved neisserial antigens |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008234959B2 (en) * | 2001-09-06 | 2012-05-17 | Novartis Vaccines And Diagnostics S.R.L. | Hybrid and tandem expression of Neisserial proteins |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001239488B2 (en) | Heterologous expression of neisserial proteins | |
| AU2001239488A1 (en) | Heterologous expression of neisserial proteins | |
| HK1071147B (en) | Heterologous expression of neisserial proteins | |
| HK1056197B (en) | Heterologous expression of neisserial proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE APPLICANT FROM CHIRON SPA TO CHIRON S.R.L. |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: GLAXOSMITHKLINE BIOLOGICALS S.A. Free format text: FORMER OWNER(S): NOVARTIS VACCINES & DIAGNOSTICS S.R.L |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |